Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Peng,Xiaoyan Qiang,Guoyu Li,Lin Li,Shumao Ni,Qi Yu,Laura Sourd,Elisabetta Marangoni,Chao Hu,Dong Wang,Di Wu,Frank Wu

DOI: https://doi.org/10.1158/1535-7163.22523257.v1

2023-01-01

Abstract:This includes the supplementary methods and supplementary table captions.

What problem does this paper attempt to address?

Figure FS9 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Peng,Xiaoyan Qiang,Guoyu Li,Lin Li,Shumao Ni,Qi Yu,Laura Sourd,Elisabetta Marangoni,Chao Hu,Dong Wang,Di Wu,Frank Wu

DOI: https://doi.org/10.1158/1535-7163.22523260

2023-01-01

Abstract:Tinengotinib possesses robust immunomodulatory activity.
Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Peng,Xiaoyan Qiang,Guoyu Li,Lin Li,Shumao Ni,Qi Yu,Laura Sourd,Elisabetta Marangoni,Chao Hu,Dong Wang,Di Wu,Frank Wu

DOI: https://doi.org/10.1158/1535-7163.mct-22-0012

2023-01-01

Molecular Cancer Therapeutics

Abstract:Triple-negative breast cancer (TNBC) is a highly heteroge-neous cancer lacking actionable targets. Using a phenotypic screen of TNBC cells, we discovered a novel multiple kinase inhibitor tinengotinib (TT-00420) that strongly inhibited Aurora A/B, FGFR1/2/3, VEGFRs, JAK1/2, and CSF1R in biochemical assays. Exposure to tinengotinib specifically inhibited prolifera-tion across all subtypes of TNBC in vitro and in vivo, while leaving luminal breast cancer cells intact. Incubation of HCC1806 with tinengotinib led to dose-dependent downregula-tion of genes essential for TNBC cell growth and proliferation. Studies revealed that the potential mechanism of action of tinengotinib involved, predominantly, inhibition of Aurora A or B kinase activity, while inhibition of other pathways contrib-uted to suppression of potency and activity. In vitro treatment of TNBC cell lines or in vivo administration in a syngeneic model with tinengotinib resulted in up-regulation of CXCL10 and 11 or diminished tumor-associated macrophage (TAM) infiltration. Tinengotinib represents a novel combinatorial inhibitory mech-anism to treat TNBC. The phase I trial of tinengotinib was completed (ClinicalTrials.gov identifier: NCT03654547).
Supplementary Materials and Methods from Serglycin is a Theranostic Target in Nasopharyngeal Carcinoma That Promotes Metastasis

Xin-Jian Li,Choon Kiat Ong,Yun Cao,Yan-Qun Xiang,Jian-Yong Shao,Aikseng Ooi,Li-Xia Peng,Wen-Hua Lu,Zhongfa Zhang,David Petillo,Li Qin,Ying-Na Bao,Fang-Jing Zheng,Claramae Shulyn Chia,N. Gopalakrishna Iyer,Tie-Bang Kang,Yi-Xin Zeng,Khee Chee Soo,Jeffrey M. Trent,Bin Tean Teh,Chao-Nan Qian

DOI: https://doi.org/10.1158/0008-5472.22390673.v1

2023-01-01

Abstract:Supplementary Materials and Methods from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis
Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Humam Kadara,Li Shen,Junya Fujimoto,Pierre Saintigny,Chi-Wan Chow,Wenhua Liu,Zuoming Chu,Melinda Garcia,Mohamed Kabbout,You-Hong Fan,Carmen Behrens,Diane A. Liu,Mao Li,J. Jack Lee,Kathryn A. Gold,Jing Wang,Kevin R. Coombes,Edward S. Kim,Waun Ki Hong,Ignacio I. Wistuba

DOI: https://doi.org/10.1158/1940-6207.22524618.v1

2023-01-01

Abstract:PDF file - 6272K, Sweave report depicting complete codes used for microarray analysis and identification of genes differentially expressed by site and time
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary Methods from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in in Vitro and in Vivo Models of Non–Small Cell Lung Cancer

Takeshi Shimamura,Samanthi A. Perera,Kevin P. Foley,Jim Sang,Scott J. Rodig,Takayo Inoue,Liang Chen,Danan Li,Julián Carretero,Yuchen Li,Papiya Sinha,Christopher D. Carey,Christa L. Borgman,John-Paul Jimenez,Matthew Meyerson,Weiwen Ying,James Barsoum,Kwok-Kin Wong,Geoffrey I. Shapiro

DOI: https://doi.org/10.1158/1078-0432.22443389

2023-01-01

Abstract:PDF file, 49K, Supplementary Immunohistochemical and Imaging Methods.
Supplemental materials from Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Qiao Li,Xiuwen Guan,Shanshan Chen,Zongbi Yi,Bo Lan,Puyuan Xing,Ying Fan,Jiayu Wang,Yang Luo,Peng Yuan,Ruigang Cai,Pin Zhang,Qing Li,Dafang Zhong,Yifan Zhang,Jianjun Zou,Xiaoyu Zhu,Fei Ma,Binghe Xu

DOI: https://doi.org/10.1158/1078-0432.22472057

2023-01-01

Abstract:Detailed protocols for ctDNA sequencing
Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Huai-Xiang Hao,Hongyun Wang,Chen Liu,Steven Kovats,Roberto Velazquez,Hengyu Lu,Bhavesh Pant,Matthew D. Shirley,Matthew J. Meyer,Minying Pu,Joanne Lim,Michael J. Fleming,LeighAnn Alexander,Ali Farsidjani,Matthew J. LaMarche,Susan E. Moody,Serena J. Silver,Giordano Caponigro,Darrin D. Stuart,Tinya J. Abrams,Peter S. Hammerman,Juliet A. Williams,Jeffrey A. Engelman,Silvia Goldoni,Morvarid Mohseni

DOI: https://doi.org/10.1158/1535-7163.22505919.v1

2023-01-01

Abstract:Supplementary Material and Methods. File contains the following: Transcriptome sequencing and analysis, Soft agar assay, 2D and 3D Cell proliferation screen and compound characterization information.
Supplemental Methods and Legends from Target Identification in Small Cell Lung Cancer Via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Jiannong Li,Bin Fang,Fumi Kinose,Yun Bai,Jae-Young Kim,Yian A. Chen,Uwe Rix,John M. Koomen,Eric B. Haura

DOI: https://doi.org/10.1158/1535-7163.22503178.v1

2023-01-01

Abstract:Supplemental methods and legends for supplemental figures S1 to S3 and supplemental tables S1 to S3
Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 through 5 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Hong-Lin Jiang,He-Fen Sun,Shui-Ping Gao,Liang-Dong Li,Sheng Huang,Xin Hu,Sheng Liu,Jiong Wu,Zhi-Ming Shao,Wei Jin

DOI: https://doi.org/10.1158/0008-5472.22409469.v1

2023-01-01

Abstract:Supplementary Materials and Methods, Supplementary Figure Legends, Supplementary Table S1 Alteration of SSBP1 protein expression levels in relation to clinicopathological characteristics in breast cancer patients. Supplementary Table S2 Antibodies used in this study. Supplementary Table S3 Primers for plasmid construction. Supplementary Table S4 Primers for ChIP. Supplementary Table S5 iTRAQ: Dysregulated proteins with gene symbol.
Supplementary Table 4 from ATR Inhibition is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Xinyi Tu,Mohamed M. Kahila,Qin Zhou,Jia Yu,Krishna R. Kalari,Liewei Wang,William S. Harmsen,Jian Yuan,Judy C. Boughey,Matthew P. Goetz,Jann N. Sarkaria,Zhenkun Lou,Robert W. Mutter

DOI: https://doi.org/10.1158/1535-7163.22504606

2023-01-01

Abstract:Supplementary Table 4 demonstrates single nucleotide variants, indels, copy number variants and copy number alterations in MCTNBC4
Supplemental Materials and Methods from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies

Yu-Wei Li,Lei-Jie Dai,Xiang-Rong Wu,Shen Zhao,Yu-Zheng Xu,Xi Jin,Yi Xiao,Ying Wang,Cai-Jin Lin,Yi-Fan Zhou,Tong Fu,Wen-Tao Yang,Ming Li,Hong Lv,Siyuan Chen,Anita Grigoriadis,Yi-Zhou Jiang,Ding Ma,Zhi-Ming Shao

DOI: https://doi.org/10.1158/0008-5472.27603358

2024-01-01

Abstract:Supplemental Materials and Methods
Supplementary Materials and Methods, Table 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Jing Ning,Dongsheng Wang,Zhongliang Hu,Hyung Ju C. Shin,Guoqing Qian,Mohammad Aminur Rahman,Hongzheng Zhang,A.R.M. Ruhul Amin,Sreenivas Nannapaneni,Xiaojing Wang,Zhengjia Chen,Gabriela García,Gavin MacBeath,Dong M. Shin,Fadlo R. Khuri,Jun Ma,Zhuo G. Chen,Nabil F. Saba

DOI: https://doi.org/10.1158/1535-7163.22501320

2023-01-01

Abstract:PDF file - 171KB, Synergistic Indices of combination treatment with MM-121 and cetuximab in different assays.
Supplementary Materials from Targeting DNA Damage Response Promotes Antitumor Immunity Through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Triparna Sen,B. Leticia Rodriguez,Limo Chen,Carminia M. Della Corte,Naoto Morikawa,Junya Fujimoto,Sandra Cristea,Thuyen Nguyen,Lixia Diao,Lerong Li,Youhong Fan,Yongbin Yang,Jing Wang,Bonnie S. Glisson,Ignacio I. Wistuba,Julien Sage,John V. Heymach,Don L. Gibbons,Lauren A. Byers

DOI: https://doi.org/10.1158/2159-8290.22532635

2023-01-01

Abstract:This file contains supplementary materials and methods; figures and figure legends and Tables.
Supplementary Materials and Methods from An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis

Xiumei Huang,Ying Dong,Erik A. Bey,Jessica A. Kilgore,Joseph S. Bair,Long-Shan Li,Malina Patel,Elizabeth I. Parkinson,Yiguang Wang,Noelle S. Williams,Jinming Gao,Paul J. Hergenrother,David A. Boothman

DOI: https://doi.org/10.1158/0008-5472.22391745

2023-01-01

Abstract:PDF file - 133K, A detailed description of all Materials and Methods used in the Supplemental Figures and Tables.
Supplementary Materials, Methods and Tables from Downregulation of safb Sustains the NF-κB Pathway by Targeting tak1 During the Progression of Colorectal Cancer

Hong‐Li Jiao,Yaping Ye,Runwei Yang,Hongbin Sun,Shuyang Wang,Yongxia Wang,Zhi-Yuan Xiao,Long He,Juan‐Juan Cai,Wanzhi Wei,Yanru Chen,Chun-Cai Gu,Yue-Long Cai,Yun-Teng Hu,Qiuhua Lai,Junfeng Qiu,Liang Li,Guangwen Cao,Wenting Liao,Yan‐Qing Ding

DOI: https://doi.org/10.1158/1078-0432.22463628.v1

2023-01-01

Abstract:Supplementary materials, methods and tables
Supplementary Figure 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in in Vitro and in Vivo Models of Non–Small Cell Lung Cancer

Takeshi Shimamura,Samanthi A. Perera,Kevin P. Foley,Jim Sang,Scott J. Rodig,Takayo Inoue,Liang Chen,Danan Li,Julián Carretero,Yuchen Li,Papiya Sinha,Christopher D. Carey,Christa L. Borgman,John-Paul Jimenez,Matthew Meyerson,Weiwen Ying,James Barsoum,Kwok-Kin Wong,Geoffrey I. Shapiro

DOI: https://doi.org/10.1158/1078-0432.22443407

2023-01-01

Abstract:PDF file, 1170K, Depletion of oncogenic drivers in NSCLC cell lines.
Supplementary Data from Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Weiping Peng,Xi Jin,Xiao‐En Xu,Yingju Yang,Ding Ma,Zhi‐Ming Shao,Yi‐Zhou Jiang

DOI: https://doi.org/10.1158/0008-5472.22732543

2023-01-01

Abstract:Supplementary methods, figures, figure legends, and tables
Supplementary Figure 1 from Pyrotinib Treatment in Patients with HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data

Munawar Anwar,Qitong Chen,Dengjie Ouyang,Shouman Wang,Ning Xie,Quchang Ouyang,Peizhi Fan,Liyuan Qian,Gannong Chen,Enxiang Zhou,Lei Guo,Xiaowen Gu,Boning Ding,Xiaohong Yang,Liping Liu,Chao Deng,Zhi Xiao,Jing Li,Yunqi Wang,Shan Zeng,Jinhui Hu,Wei Zhou,Bo Qiu,Zhongming Wang,Jie Weng,Mingwen Liu,Yi Li,Tiegang Tang,Jianguo Wang,Hui Zhang,Bin Dai,Wuping Tang,Tao Wu,Maoliang Xiao,Xiantao Li,Hailong Liu,Lai Li,Wenjun Yi

DOI: https://doi.org/10.1158/1078-0432.27183567

2024-01-01

Abstract:Survival analysis according to treatment line, hormone receptor status and metastatic sites.
Supplementary Materials and Methods from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Lu Xu,Eiki Kikuchi,Chunxiao Xu,Hiromichi Ebi,Dalia Ercan,Katherine A. Cheng,Robert Padera,Jeffrey A. Engelman,Pasi A. Jänne,Geoffrey I. Shapiro,Takeshi Shimamura,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22391816.v1

2023-01-01

Abstract:PDF file - 329K, Procedures for xenografts and a list of antibodies used for IHC and Western blots

Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Figure FS9 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Supplementary Materials and Methods from Serglycin is a Theranostic Target in Nasopharyngeal Carcinoma That Promotes Metastasis

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Methods from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>in Vitro</i> and <i>in Vivo</i> Models of Non–Small Cell Lung Cancer

Supplemental materials from Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplemental Methods and Legends from Target Identification in Small Cell Lung Cancer Via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 through 5 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Supplementary Table 4 from ATR Inhibition is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Supplemental Materials and Methods from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies

Supplementary Materials and Methods, Table 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Materials from Targeting DNA Damage Response Promotes Antitumor Immunity Through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Supplementary Materials and Methods from An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis

Supplementary Materials, Methods and Tables from Downregulation of <i>safb</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>tak1</i> During the Progression of Colorectal Cancer

Supplementary Figure 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>in Vitro</i> and <i>in Vivo</i> Models of Non–Small Cell Lung Cancer

Supplementary Data from Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Supplementary Figure 1 from Pyrotinib Treatment in Patients with HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data

Supplementary Materials and Methods from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Figure FS9 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Supplementary Materials and Methods from Serglycin is a Theranostic Target in Nasopharyngeal Carcinoma That Promotes Metastasis

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Methods from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in &lt;i&gt;in Vitro&lt;/i&gt; and &lt;i&gt;in Vivo&lt;/i&gt; Models of Non–Small Cell Lung Cancer

Supplemental materials from Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplemental Methods and Legends from Target Identification in Small Cell Lung Cancer Via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 through 5 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Supplementary Table 4 from ATR Inhibition is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Supplemental Materials and Methods from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies

Supplementary Materials and Methods, Table 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Materials from Targeting DNA Damage Response Promotes Antitumor Immunity Through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Supplementary Materials and Methods from An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis

Supplementary Materials, Methods and Tables from Downregulation of &lt;i&gt;safb&lt;/i&gt; Sustains the NF-&lt;b&gt;κ&lt;/b&gt;B Pathway by Targeting &lt;i&gt;tak1&lt;/i&gt; During the Progression of Colorectal Cancer

Supplementary Figure 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in &lt;i&gt;in Vitro&lt;/i&gt; and &lt;i&gt;in Vivo&lt;/i&gt; Models of Non–Small Cell Lung Cancer

Supplementary Data from Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Supplementary Figure 1 from Pyrotinib Treatment in Patients with HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data

Supplementary Materials and Methods from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Methods from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>in Vitro</i> and <i>in Vivo</i> Models of Non–Small Cell Lung Cancer

Supplementary Materials, Methods and Tables from Downregulation of <i>safb</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>tak1</i> During the Progression of Colorectal Cancer

Supplementary Figure 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>in Vitro</i> and <i>in Vivo</i> Models of Non–Small Cell Lung Cancer